Combination anti-VEGF and corticosteroid therapy for idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome

Ophthalmic Surg Lasers Imaging Retina. 2013 Nov 1;44(6):599-602. doi: 10.3928/23258160-20131105-09.

Abstract

Vision loss associated with the idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome most commonly occurs from macular edema or complications related to neovascularization. The authors present a case of advanced IRVAN associated with a massive exudative response characterized by peripheral retinal telangiectasias, exudative retinal detachment, and macular edema with lipid maculopathy. The patient was managed successfully with visual acuity from hand motion to 20/150 using a combination of local corticosteroids, intravitreal bevacizumab, panretinal photocoagulation, and eventually pars plana vitrectomy for progressive vitreomacular traction. VEGF- and non-VEGF-mediated mechanisms appear to be involved in the pathogenesis of IRVAN given the efficacy of combination therapy. [ophthalmic surg lasers imaging retina. 2013;44:599-602.].

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Aneurysm / diagnosis
  • Aneurysm / therapy*
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Combined Modality Therapy / methods
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Light Coagulation / methods
  • Retinal Vasculitis / diagnosis
  • Retinal Vasculitis / therapy*
  • Retinitis / diagnosis
  • Retinitis / therapy*
  • Treatment Outcome
  • Vitrectomy / methods

Substances

  • Adrenal Cortex Hormones
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab